BACKGROUND: Single nucleotide polymorphisms can create a genetic microenvironment in some tumors that affects the course of treatment, resistance, etc. Whether single nucleotide polymorphisms have an impact on gastrointestinal stromal tumor (GIST) development and disease progression is not yet accurately verified. KIT SNPM541L in exon 10 correlates with a worse prognosis of many cancers. The impact of KIT SNPM541L in GISTs is relatively unknown and, therefore, its analyses could have potential in patient therapy and could provide more detailed information on tumor character, clinical presentation, or tumor behavior in treatment. AIM: The aim of the study was the analysis of the biological and clinical significance of the KIT SNPM541L polymorphism in exon 10. MATERIALS AND METHODS: Paraffin sample tissues were obtained from the National GIST Register in Martin. Retrospective samples from 177 GIST patients were divided into several groups. Detection of SNPM541L was performed by Sanger sequencing. Statisitical analyses were performed to determine the prevalence of KIT SNPM541L in the Slovak GIST cohort, to search for correlation between c-KIT status and clinicopathological, molecular and biological data. RESULTS: Overall, 29 samples out of 177 showed KIT SNPM541L polymorphism. CONCLUSION: Our results do not support the association between KIT SNPM541L and increased risk of relapse in localized primary GISTs. Additionally, we found a positive correlation between KIT SNPM541L occurrence and earlier onset of relapse in PDGFRa and WT subgroup of GISTs.

2nd Department of Internal Medicine Faculty of Medicine Masaryk University and St Anne'S University Hospital Brno Czech Republic

Biomedical Center Martin Jessenius Faculty of Medicine in Martin Comenius University in Bratislava Martin Slovakia

Department of Medicine A O U 1 Policlinico G B Rossi and University of Verona Verona Italy

Department of Molecular Biology and Genomics Jessenius Faculty of Medicine in Martin Comenius University in Bratislava Martin Slovakia

Department of Pathological Anatomy Jessenius Faculty of Medicine in Martin Comenius University in Bratislava Martin Slovakia

Faculty of Medicine University of Oviedo Central University Hospital of Asturias Oviedo Spain

Research and Development Services Brno Czech Republic

Zobrazit více v PubMed

Alvi MA, Loughrey MB, Dunne P, McQuaid S, Turkington R, Fuchs MA, McGready C, Bingham V, Pang B, Moore W, Maxwell P, Lawler M, James JA, Murray GI, Wilson RH, Salto-Tellez M et al (2017) Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Br J Cancer 117:203–209 DOI

Angelini S, Ravegnini G, Nannini M, Bermejo JL, Musti M, Pantaleo MA, Fumagalli E, Venturoli N, Palassini E, Consolini N, Casali PG, Biasco G, Hrelia P (2015) Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Eur J Hum Genet 23:817–823 DOI

Barbano R, Pasculli B, Coco M, Fontana A, Copetti M, Rendina M, Valori VM, Graziano P, Maiello E, Fazio VM, Parrella P (2015) Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. Sci Rep 5:18592 DOI

Brahmi M, Alberti L, Dufresne A, Ray-Coquard I, Cassier P, Meeus P, Decouvelaere AV, Ranchère-Vince D, Blay JP (2015) KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome. BMC Cancer 15:780 DOI

Chevrier S, Arnould L, Ghiringhelli F, Coudert B, Fumoleau P, Boidot R (2014) Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations. Int J Oncol 45:1167–1174 DOI

Deng N, Zhou H, Fan H, Yuan Y (2017) Single nucleotide polymorphisms and cancer susceptibility. Oncotarget 8:110635–110649 DOI

Dufresne A, Alberti L, Brahmi M, Kabani S, Philippon H, Pérol D, Blay JY (2014) Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. BMC Cancer 14:632 DOI

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley J, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465 DOI

Foster R, Byrnes E, Meldrum C, Griffith R, Ross G, Upjohn E, Braue A, Scott R, Varigos G, Ferrao P, Ashman LK (2008) Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. Br J Dermatol 159:1160–1169 PubMed

Ghagane S, Nerli RB, Kaliwal BB, Hiremath MB (2016) Single nucleotide polymorphisms: a new paradigm in predicting the risk of prostate cancer. Cell Dev Biol 5:1000168 DOI

Grabellus F, Worm K, Sheu SY, Siffert W, Schmid KW, Bachmann HS (2011) The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population. J Clin Pathol 64:1021–1024 DOI

Hoade Y, Metzgeroth G, Schwaab J, Reiter A, Cross NCP (2018) Routine Screening for KIT M541L Is Not Warranted in the Diagnostic Work-Up of Patients with Hypereosinophilia. Acta Haematol 139:71–73 DOI

Hurley RH, McCormick M, Elhassan M, Nicholson G (2018) Gastrointestinal stromal tumour as a rare association with neurofibromatosis type 1. J Surg Case Rep 2:2

Huss S, Künstlinger H, Wardelmann E, Kleine MA, Binot E, Merkelbach-Bruse S, Rüdiger T, Mittler J, Hartmann W, Büttner R, Schildhaus HU (2013) A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p. D419del). Mod Pathol 26:1004–1012 DOI

Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S, Dan K (2002) Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia–potential clinical significance. Leukemia 16:170–177 DOI

Ito T, Yamamura M, Hirai T, Ishikawa T, Kanda T, Nakai T, Ohkouchi M, Hashikura Y, Isozaki K, Hirota S (2014) Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature. Int J Clin Exp Pathol 7:8024–8031 PubMed PMC

Iurlo A, Gianelli U, Beghini A, Spinelli O, Orofino N, Lazzaroni F, Cambiaghi S, Intermesoli T, Rambaldi A, Cortelezzi A (2014) Identification of kit (M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. Oncotarget 4665–4670.

Jasek K, Buzalkova V, Minarik G, Stanclova A, Szepe P, Plank L, Lasabova Z (2017) Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors. Virchows Arch 470:29–36 DOI

Ke H, Kazi JU, Zhao H, Sun J (2016) Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis. Cell Biosci 6:55 DOI

Krasagakis K, Metaxari M, Zervou M, Stathopoulos EN, Eberle J, Kanitakis J, Georgoulias V, Krüger-Krasagakis S, Tavernarakis N, Tosca AD (2011) Identification of the M541L sequence variation of the transmembrane KIT domain in Merkel cell carcinoma. Anticancer Res 31:807–811 PubMed

Krüger S, Emig M, Lohse P, Ehninger G, Hochhaus A, Schackert HK (2006) The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians. Leukemia 20:354–355 DOI

Lasota J, Felisiak-Golabek A, Wasag B, Kowalik A, Zięba S, Chłopek M, Wang ZF, Coates T, Kopczynski J, Gozdz S, Sarlomo-Rikala M, Miettinen M (2016) Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases. Mod Pathol 29:275–282 DOI

Laytragoon-Lewin N, Cederblad L, Andersson BÅ, Olin M, Nilsson M, Rutqvist LE, Lundgren J, Engström M, Tytor W, Löfgren S, Lewin F (2017) Single-nucleotide polymorphisms and cancer risk, tumor recurrence, or survival of head and neck cancer patients. Oncology 92:161–169 DOI

Li K, Cheng H, Li Z, Pang Y, Jia X, Xie F, Hu G, Cai Q, Wang Y (2017) Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. Oncotarget 8:60589–60604 DOI

Masago K, Fujita S, Muraki M, Hata A, Okuda C, Otsuka K, Kaji R, Takeshita J, Kato R, Katakami N, Hirata Y (2015) Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer 15:908 DOI

Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83 DOI

Minarik G, Plank L, Lasabova Z, Szemes T, Burjanivova T, Szepe P, Buzalkova V, Porubsky D, Sufliarsky J (2013) Spectrum of mutations in gastrointestinal stromal tumor patients—a population based study from Slovakia. APMIS 121:539–548 DOI

Nannini M, Astolfi A, Urbini M, Indio V, Santini D, Heinrich MC, Corless CL, Ceccarelli C, Saponara M, Mandrioli A, Lolli C, Ercolani G, Brandi G, Biasco G, Pantaleo MA (2014) Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer 14:685 DOI

Niinuma T, Suzuki H, Sugai T (2018) Molecular characterization and pathogenesis of gastrointestinal stromal tumor. Transl Gastroenterol Hepatol 9:3

Noujaim J, Gonzalez D, Thway K, Jones RL, Judson J (2016) p. (L576P) -KIT mutation in GIST: favorable prognosis and sensitive to imatinib? Cancer Biol Ther 17:543–545 DOI

O’Brien KM, Orlow I, Antonescu CR, Ballman K, McCall L, DeMatteo R, Engel LS (2013a) Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants. PLoS ONE 8:e62119 DOI

O’Brien KM, Orlow I, Antonescu CR, Ballman K, McCall L, DeMatteo R, Engel LS (2013b) Gastrointestinal stromal tumors: a case-only analysis of single nucleotide polymorphisms and somatic mutations. Clin Sarcoma Res 3:12 DOI

Péčová T, Vorčáková K, Žaliová M, Burjanivová T, Malicherová B, Plank L, Trka J, Péčová K, Adamicová K, Péč M, Pec J (2018) Testicular cancer in monozygotic twin brothers with urticaria pigmentosa. Acta Derm Venereol 98:528–529 DOI

Pedersen M, Rönnstrand L, Sun J (2009) The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. Cell Signal 21:413–418 DOI

Plank L, Buzalkova V, Szepe P, Lasabova Z, Jasek K, Stanclova A, Minarik G, Sufliarsky J (2017) Gastrointestinal stromal tumor after tyrosine kinase inhibition therapy: a review of biopsies of 34 patients with clinically suspected relapse and/or progression of the tumor. Neoplasma 64:464–473 DOI

Quek R, George S (2010) Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics 4:19–31 PubMed PMC

Rocha J, Luz Duarte M, Marques H, Torres F, Tavares P, Silva A, Brito C (2010) Association of adult mastocytosis with M541L in the transmembrane domain of KIT. J Eur Acad Dermatol Venereol 24:1118–1119 PubMed